Hormonal
Adopting a low-glycemic index (GI) or low-glycemic load diet promotes greater weight loss and improves metabolic health compared to conventional low-fat diets, primarily by modulating post-prandial insulin and glucagon ratios to favor fat oxidation and preserve lean body tissue.
To manage weight and metabolic health, prioritize carbohydrates that digest slowly. Replace refined grains, sugars, and processed snacks with legumes, whole grains, non-starchy vegetables, and nuts. This approach helps stabilize blood sugar and insulin levels, reducing hunger and promoting fat loss more effectively than simply reducing fat intake alone.
Weight-reducing low GI diets, by contrast, may have more favourable effects on appetite and long-term metabolism, improving the probability of success.
Why this rating
Supported by multiple short-term human trials, animal studies, and epidemiological data, though long-term human trials are noted as lacking.
Source
Should obese patients be counselled to follow a low‐glycaemic index diet? Yes
Dorota B Pawlak et al. · Obesity Reviews · 2002
DOI 10.1046/j.1467-789x.2002.00079.x
More from this paper
- Low-glycemic index diets reduce the risk of cardiovascular disease and type 2 diabetes by improving lipid profiles (lowering triglycerides, raising HDL) and reducing markers of inflammation and insulin resistance.Good
- Low-glycemic index diets increase satiety and reduce voluntary food intake by flattening post-prandial glucose and insulin curves, thereby preventing reactive hypoglycemia and subsequent hunger spikes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →